Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer
Phase 3
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-08-19
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 376
- Registration Number
- NCT00961415
A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: tocilizumab [RoActemra/Actemra]Drug: Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 105
- Registration Number
- NCT00951275
- Locations
- 🇮🇹
Policlinico Tor Vergata; Divisione Di Reumatologia, Roma, Lazio, Italy
🇮🇹Ospedale San Paolo; Divisione di Reumatologia, Savona, Liguria, Italy
🇮🇹Az. Ospedaliera Univ. di Parma; Medicina Interna e Reumatologia, Parma, Emilia-Romagna, Italy
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2009-07-31
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6586
- Registration Number
- NCT00949910
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-07-31
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 596
- Registration Number
- NCT00950300
- Locations
- 🇦🇷
Centro Medico San Roque; Oncology Dept, Tucuman, Argentina
🇭🇺Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, Hungary
🇲🇽Hospital Privado San Jose; Oncologia, Obregon, Mexico
A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 132
- Registration Number
- NCT00949702
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸University of Colorado, Denver, Colorado, United States
🇺🇸UCLA - School of Medicine; Division of Hematology/Oncology, Los Angeles, California, United States
A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2016-08-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 37
- Registration Number
- NCT00949533
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Phase 3
Completed
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 921
- Registration Number
- NCT00943826
- Locations
- 🇧🇪
CHU Sart-Tilman, Liège, Belgium
🇺🇸University of Virgina, Charlottesville, Virginia, United States
🇫🇷Centre Georges François Leclerc, Dijon, France
A Study of Xenical (Orlistat) in Overweight and Obese Adolescents
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT00940628
OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT00940303
A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Copegus (ribavirin)Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2695
- Registration Number
- NCT00940420
© Copyright 2025. All Rights Reserved by MedPath